Researchers create molecule that could 'kick and kill' HIV

October 5, 2017, University of California, Los Angeles
The scientists' approach sends an agent to "wake up" the dormant virus, causing it to begin replicating so that either the immune system or the virus itself would kill the cell harboring HIV. Credit: CDC/A. Harrison and Dr. P. Feorino

Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly reduce the chance of transmission from person to person.

But the medications do not actually rid the body of the , which has the ability to elude medications by lying dormant in called CD4+ T cells, which signal another type of T cell, the CD8, to destroy HIV-infected cells. When a person with HIV stops treatment, the virus emerges and replicates in the body, weakening the immune system and raising the likelihood of opportunistic infections or cancers that can sicken or kill the patient.

Researchers have been looking for ways to eliminate the "reservoirs" where the virus hides, and researchers from UCLA, Stanford University and the National Institutes of Health may have developed a solution. Their approach involves sending an agent to "wake up" the dormant virus, which causes it to begin replicating so that either the immune system or the virus itself would kill the cell harboring HIV.

Scientists call the technique "kick and kill."

Destroying the reservoir cells could rid some or all of the HIV virus from people who are infected. And although the scientists' approach has not been tested in humans yet, a synthetic molecule they developed has been effective at kicking and killing HIV in lab animals, according to a study published Sept. 21 in the peer-reviewed journal PLOS Pathogens.

"The latent HIV reservoir is very stable and can reactivate if a patient stops taking for any reason," said Matthew Marsden, an assistant professor of medicine in the division of hematology oncology at the David Geffen School of Medicine at UCLA, and the study's lead author. "Our study suggests that there may be means of activating latent virus in the body while the patient is on antiretroviral drugs to prevent the virus from spreading, and that this may eliminate at least some of the latent reservoir."

To test the approach, the researchers gave antiretroviral drugs to mice that had been infected with HIV, and then administered a synthetic compound called SUW133, which was developed at Stanford, to activate the mice's dormant HIV. Up to 25 percent of the previously dormant cells that began expressing HIV died within 24 hours of activation.

With further development, the technique could lower the viral reservoir enough for people with HIV to be able to discontinue their anti-viral therapy, Marsden said.

SUW133 is based on bryostatin 1, a natural compound extracted from a marine animal called Bugula neritina. The research determined that the new compound is less toxic than the naturally occurring version.

"The findings are significant because several previous attempts to activate latent virus have had only limited success," said senior author Jerome Zack, professor and chair of the UCLA department of microbiology, immunology and molecular genetics at the Geffen School, and director of the UCLA Center for AIDS Research. "Most studies showed weak activation of the virus, or severe toxicity, with little effect on the reservoir."

Marsden said results in mice will not necessarily translate to humans. In further studies, the scientists plan to learn how to make SUW133's less toxic, and to evaluate its effectiveness in larger animals, before it could be tested in humans.

The study's other authors are Xiaomeng Wu and Christina Ramirez of UCLA; Brian Loy, Adam Schrier, Akira Shimizu, Steven Ryckbosch, Katherine Near and Paul Wender of Stanford; and Danielle Murray and Tae-Wook Chun of the NIH's National Institute of Allergy and Infectious Diseases.

Explore further: Synthetic molecule 'kicks and kills' some persistent HIV in mice

Related Stories

Synthetic molecule 'kicks and kills' some persistent HIV in mice

September 21, 2017
Scientists have designed a synthetic molecule that can reactivate dormant human immunodeficiency virus (HIV) in mice and lead to the death of some of the infected cells, according to a study published in PLOS Pathogens.

A new method for removing cells infected with the AIDS virus

October 2, 2017
With the successful suppression of the AIDS virus (HIV) through medication, the focus turns toward its eradication. Researchers from Kumamoto University in Japan have developed a new compound that is key to the destruction ...

Study observes potential breakthrough in treatment of HIV

June 17, 2016
A new study conducted by researchers at the San Francisco VA Medical Center (SFVAMC) observes that pharmacological enhancement of the immune systems of HIV patients could help eliminate infected cells, providing an important ...

Toward an HIV cure: Research team develops test to detect hidden virus

May 29, 2017
The quest to develop a cure for HIV has long been plagued by a seemingly simple question: How do doctors determine if someone is cured? The virus has a knack for lying dormant in immune cells at levels undetectable to all ...

Study reveals a new method to address a major barrier to eradicating HIV

May 10, 2017
Scientists at the Gladstone Institutes discovered that an enzyme called SMYD2 could be a new therapeutic target for flushing out the HIV that hides in infected individuals. Overcoming this latent virus remains the most significant ...

Designed drug candidate significantly reduces HIV reactivation rate

July 8, 2015
HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

4 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

evelynrhodes186
not rated yet Oct 05, 2017
That is all fine and dandy, but what about a straight out cure and not just being able to not take the meds, but still have the virus.
zave
not rated yet Oct 06, 2017
Be patient they will get to it.This is a great step in that direction.
WishingOnAStar
not rated yet Oct 08, 2017
Yes..it is coming. The burden exists from having to take daily meds, more frequent monitoring at various doctor's visits for other disease prevention, and the comorbidities that accrue as one ages in terms of healthcare costs. The other burden comes from needing to disclose health status and the rejection caused by stigma because of said disclosure. Casual "intimacy" comes with anxiety on the low end and possible alleged assault on the high.
moeshawalter
not rated yet Nov 24, 2017
for herbal medicine to cure hiv and other std, contact dr. kpomosa a herbalist in the fight to eradicate hiv, and other deadly virus.
dr.kpomosa@outlook.com he has all the answers.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.